Cargando…

Circulating Microbiota in Cardiometabolic Disease

The rapid expansion of microbiota research has significantly advanced our understanding of the complex interactions between gut microbiota and cardiovascular, metabolic, and renal system regulation. Low-grade chronic inflammation has long been implicated as one of the key mechanisms underlying cardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sumida, Keiichi, Han, Zhongji, Chiu, Chi-Yang, Mims, Tahliyah S., Bajwa, Amandeep, Demmer, Ryan T., Datta, Susmita, Kovesdy, Csaba P., Pierre, Joseph F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110890/
https://www.ncbi.nlm.nih.gov/pubmed/35592652
http://dx.doi.org/10.3389/fcimb.2022.892232
_version_ 1784709203492864000
author Sumida, Keiichi
Han, Zhongji
Chiu, Chi-Yang
Mims, Tahliyah S.
Bajwa, Amandeep
Demmer, Ryan T.
Datta, Susmita
Kovesdy, Csaba P.
Pierre, Joseph F.
author_facet Sumida, Keiichi
Han, Zhongji
Chiu, Chi-Yang
Mims, Tahliyah S.
Bajwa, Amandeep
Demmer, Ryan T.
Datta, Susmita
Kovesdy, Csaba P.
Pierre, Joseph F.
author_sort Sumida, Keiichi
collection PubMed
description The rapid expansion of microbiota research has significantly advanced our understanding of the complex interactions between gut microbiota and cardiovascular, metabolic, and renal system regulation. Low-grade chronic inflammation has long been implicated as one of the key mechanisms underlying cardiometabolic disease risk and progression, even before the insights provided by gut microbiota research in the past decade. Microbial translocation into the bloodstream can occur via different routes, including through the oral and/or intestinal mucosa, and may contribute to chronic inflammation in cardiometabolic disease. Among several gut-derived products identifiable in the systemic circulation, bacterial endotoxins and metabolites have been extensively studied, however recent advances in microbial DNA sequencing have further allowed us to identify highly diverse communities of microorganisms in the bloodstream from an -omics standpoint, which is termed “circulating microbiota.” While detecting microorganisms in the bloodstream was historically considered as an indication of infection, evidence on the circulating microbiota is continually accumulating in various patient populations without clinical signs of infection and even in otherwise healthy individuals. Moreover, both quantitative and compositional alterations of the circulating microbiota have recently been implicated in the pathogenesis of chronic inflammatory conditions, potentially through their immunostimulatory, atherogenic, and cardiotoxic properties. In this mini review, we aim to provide recent evidence on the characteristics and roles of circulating microbiota in several cardiometabolic diseases, such as type 2 diabetes, cardiovascular disease, and chronic kidney disease, with highlights of our emerging findings on circulating microbiota in patients with end-stage kidney disease undergoing hemodialysis.
format Online
Article
Text
id pubmed-9110890
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91108902022-05-18 Circulating Microbiota in Cardiometabolic Disease Sumida, Keiichi Han, Zhongji Chiu, Chi-Yang Mims, Tahliyah S. Bajwa, Amandeep Demmer, Ryan T. Datta, Susmita Kovesdy, Csaba P. Pierre, Joseph F. Front Cell Infect Microbiol Cellular and Infection Microbiology The rapid expansion of microbiota research has significantly advanced our understanding of the complex interactions between gut microbiota and cardiovascular, metabolic, and renal system regulation. Low-grade chronic inflammation has long been implicated as one of the key mechanisms underlying cardiometabolic disease risk and progression, even before the insights provided by gut microbiota research in the past decade. Microbial translocation into the bloodstream can occur via different routes, including through the oral and/or intestinal mucosa, and may contribute to chronic inflammation in cardiometabolic disease. Among several gut-derived products identifiable in the systemic circulation, bacterial endotoxins and metabolites have been extensively studied, however recent advances in microbial DNA sequencing have further allowed us to identify highly diverse communities of microorganisms in the bloodstream from an -omics standpoint, which is termed “circulating microbiota.” While detecting microorganisms in the bloodstream was historically considered as an indication of infection, evidence on the circulating microbiota is continually accumulating in various patient populations without clinical signs of infection and even in otherwise healthy individuals. Moreover, both quantitative and compositional alterations of the circulating microbiota have recently been implicated in the pathogenesis of chronic inflammatory conditions, potentially through their immunostimulatory, atherogenic, and cardiotoxic properties. In this mini review, we aim to provide recent evidence on the characteristics and roles of circulating microbiota in several cardiometabolic diseases, such as type 2 diabetes, cardiovascular disease, and chronic kidney disease, with highlights of our emerging findings on circulating microbiota in patients with end-stage kidney disease undergoing hemodialysis. Frontiers Media S.A. 2022-05-03 /pmc/articles/PMC9110890/ /pubmed/35592652 http://dx.doi.org/10.3389/fcimb.2022.892232 Text en Copyright © 2022 Sumida, Han, Chiu, Mims, Bajwa, Demmer, Datta, Kovesdy and Pierre https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Sumida, Keiichi
Han, Zhongji
Chiu, Chi-Yang
Mims, Tahliyah S.
Bajwa, Amandeep
Demmer, Ryan T.
Datta, Susmita
Kovesdy, Csaba P.
Pierre, Joseph F.
Circulating Microbiota in Cardiometabolic Disease
title Circulating Microbiota in Cardiometabolic Disease
title_full Circulating Microbiota in Cardiometabolic Disease
title_fullStr Circulating Microbiota in Cardiometabolic Disease
title_full_unstemmed Circulating Microbiota in Cardiometabolic Disease
title_short Circulating Microbiota in Cardiometabolic Disease
title_sort circulating microbiota in cardiometabolic disease
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110890/
https://www.ncbi.nlm.nih.gov/pubmed/35592652
http://dx.doi.org/10.3389/fcimb.2022.892232
work_keys_str_mv AT sumidakeiichi circulatingmicrobiotaincardiometabolicdisease
AT hanzhongji circulatingmicrobiotaincardiometabolicdisease
AT chiuchiyang circulatingmicrobiotaincardiometabolicdisease
AT mimstahliyahs circulatingmicrobiotaincardiometabolicdisease
AT bajwaamandeep circulatingmicrobiotaincardiometabolicdisease
AT demmerryant circulatingmicrobiotaincardiometabolicdisease
AT dattasusmita circulatingmicrobiotaincardiometabolicdisease
AT kovesdycsabap circulatingmicrobiotaincardiometabolicdisease
AT pierrejosephf circulatingmicrobiotaincardiometabolicdisease